Funding will help advance the clinical development of firm's flagship drug for the treatment of solid and blood cancers via multiple clinical trials

Texas's Cancer Focus Fund will support a Phase 1/2 clinical study assessing Israeli company's flagship drug, which uses 2 proteins - 1 to mark cancer cells and 1 to weaken them

KAHR's leading drug candidate, now in clinical trials, is based on a compound that targets cancer cells, weakens their defenses and activates a local immune response

Drug developed by Jerusalem-based startup targets cancer cells, weakens their defenses, and activates a local response, company says; Swiss pharma firm Roche to join trials

DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them